Blue Trust Inc. Has $353,000 Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Blue Trust Inc. boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,056 shares of the medical research company’s stock after purchasing an additional 197 shares during the quarter. Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $353,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. UMB Bank n.a. grew its holdings in shares of Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after buying an additional 45 shares during the period. Wahed Invest LLC grew its stake in Bio-Rad Laboratories by 14.0% in the first quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock valued at $138,000 after acquiring an additional 49 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Bio-Rad Laboratories by 7.7% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock worth $289,000 after purchasing an additional 60 shares during the period. Capital Advisors Ltd. LLC lifted its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 62 shares in the last quarter. Finally, Natixis grew its position in shares of Bio-Rad Laboratories by 3.4% in the 1st quarter. Natixis now owns 1,986 shares of the medical research company’s stock valued at $687,000 after purchasing an additional 65 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 1.4 %

Bio-Rad Laboratories stock opened at $335.21 on Thursday. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $364.24. The company has a fifty day simple moving average of $331.15 and a 200 day simple moving average of $307.25. The company has a market cap of $9.56 billion, a P/E ratio of -32.36 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, August 1st. The medical research company reported $3.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business had revenue of $638.50 million for the quarter, compared to the consensus estimate of $645.79 million. During the same quarter in the previous year, the business earned $3.00 earnings per share. Bio-Rad Laboratories’s quarterly revenue was down 6.3% on a year-over-year basis. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on BIO. Royal Bank of Canada restated an “outperform” rating and set a $401.00 target price on shares of Bio-Rad Laboratories in a report on Friday, August 16th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Citigroup upgraded Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and increased their target price for the stock from $350.00 to $400.00 in a report on Tuesday, October 1st. Finally, Wells Fargo & Company started coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $368.20.

Insiders Place Their Bets

In other news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company’s stock, valued at $48,582.03. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.